Efficacy of Galium-68 DOTATATE PET/CT in the Detection of Metastasis Rate of Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors

Efficacy of Galium-68 DOTATATE PET/CT in the Detection of Metastasis Rate of Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors

Objective(s): The aim of this study was to determine metastasis rate in patients with well-differentiated grade1 (G1) and grade 2 (G2) gastroenteropancreatic neuroendocrine tumors (GEP NETs) using the gallium-68 DOTATATE positron emission tomography/computed tomography (68Ga-DOTATATE PET/CT). This s...

Full description

Bibliographic Details
Main Authors:	Halil Komek, Tansel Ansal Balci, Canan Can
Format:	Article
Language:	English
Published:	Mashhad University of Medical Sciences 2019-06-01
Series:	Asia Oceania Journal of Nuclear Medicine and Biology
Subjects:	Gastro-Entero-Pancreatic (GEP) Neuroendocrine Tumor (NET) [68Ga]DOTATATE PET/CT
Online Access:	http://aojnmb.mums.ac.ir/article_13348_ff4c30bc5a1bd61fe1eddd0cd8c5ace3.pdf

Similar Items

Gastrointestinal neuroendocrine tumor with discordant metastatic disease on 111In-pentetreotide SPECT/CT, 18F-DOPA PET/CT and 68Ga-HA-DOTATATE PET/CT
by: Abele, J., et al.
Published: (2022)

68Ga DOTATATE Uptake in Hemangioma Simulating Metastasis on PET Imaging
by: Bart Vertenten, et al.
Published: (2019-06-01)

Radiomics-Based Texture Analysis of 68Ga-DOTATATE Positron Emission Tomography and Computed Tomography Images as a Prognostic Biomarker in Adults With Neuroendocrine Cancers Treated With 177Lu-DOTATATE
by: Charlotte Atkinson, et al.
Published: (2021-08-01)

Pulmonary large cell neuroendocrine carcinoma (LCNEC) with confirmed liver metastases negative on 18F-FDG and 68Ga-DOTATATE PET
by: Gaia Ninatti, et al.
Published: (2020-12-01)

Gastroenteropancreatic Neuroendocrine Tumors in Multiple Endocrine Neoplasia Type 1
by: Maria Luisa Brandi, et al.
Published: (2012-05-01)

Metastatic urinary bladder paraganglioma on Ga-68 DOTATATE PET/CT
by: Andrew Ko, BSA, et al.
Published: (2021-09-01)

Diagnostic efficiency of 68Ga-DOTATATE PET/CT as compared to 99mTc-Octreotide SPECT/CT and conventional morphologic modalities in neuroendocrine tumors
by: Babak Fallahi, et al.
Published: (2019-06-01)

Is 68Ga-DOTATATE the answer in lung carcinoid? : Case report and review of literature
by: Amit Bhoil, et al.
Published: (2012-01-01)

Changes in biodistribution on 68Ga-DOTA-Octreotate PET/CT after long acting somatostatin analogue therapy in neuroendocrine tumour patients may result in pseudoprogression
by: Martin H. Cherk, et al.
Published: (2018-01-01)

Case report 68Ga-DOTATATE of optic nerve sheath meningioma
by: Adeleh Yarmohammadi, et al.
Published: (2021-06-01)

Diagnostic Utility of PET CT in Thymic Tumours with Emphasis on 68Ga-DOTATATE PET CT in Thymic Neuroendocrine Tumour - Experience at a Tertiary Level Hospital in India
by: Julie Hephzibah, et al.
Published: (2014-09-01)

Prevalence of hitherto unknown brain meningioma detected on 68Ga-DOTATATE positron-emission tomography/computed tomography in patients with metastatic neuroendocrine tumor and exploring potential of177Lu-DOTATATE peptide receptor radionuclide therapy as single-shot treatment approach targeting both tumors
by: Rahul V Parghane, et al.
Published: (2019-01-01)

Initial clinical evaluation of indigenous90Y-DOTATATE in sequential duo-PRRT approach (177Lu-DOTATATE and90Y-DOTATATE) in neuroendocrine tumors with large bulky disease: Observation on tolerability,90Y-DOTATATE post- PRRT imaging characteristics (bremsstrahlung and PETCT) and early adverse effects
by: Rahul V Parghane, et al.
Published: (2021-01-01)

68Ga-DOTATATE PET/CT Compared with 131I-MIBG SPECT/CT in the Evaluation of Neural Crest Tumors
by: Pezhman Shahrokhi, et al.
Published: (2020-01-01)

A physiologically based pharmacokinetic (PBPK) model to describe organ distribution of 68Ga-DOTATATE in patients without neuroendocrine tumors
by: H. Siebinga, et al.
Published: (2021-08-01)

68Ga-DOTATATE PET imaging in clinically non-functioning pituitary macroadenomas
by: Tessel M. Boertien, et al.
Published: (2020-02-01)

Gastroenteropancreatic neuroendocrine neoplasms: genes, therapies and models
by: Kenta Kawasaki, et al.
Published: (2018-02-01)

mTOR Pathway in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NETs)
by: Sara Zanini, et al.
Published: (2020-11-01)

Demonstration of focal physiologic in-vivo somatostatin receptor expression in the caput epididymis of the testes on 68Ga-DOTANOC PET/CT and 177Lu-DOTATATE post-therapy whole body scintigraphy
by: Ashwin Parihar, et al.
Published: (2020-07-01)

Comparison of 18F‐FDG PET/CT and 68Ga‐DOTATATE PET/CT in the Targeted Imaging of Culprit Tumors Causing Osteomalacia
by: Hao‐nan Yu, et al.
Published: (2021-05-01)

Metastatic large cell neuroendocrine carcinoma of larynx: Individualizing tumor biology by dual tracer positron emission tomography/computed tomography (68Ga-DOTATATE and18F-fluorodeoxyglucose) molecular imaging and disease stabilization following177Lu-DOTATATE peptide receptor radionuclide therapy after initial progression on chemoradiotherapy
by: Sonali Jadhav, et al.
Published: (2019-01-01)

Incidental primary breast cancer detected on surveillance 68Ga-DOTATATE PET/CT in a patient with metastatic neuroendocrine carcinoma
by: Emily B. Ambinder, MD, et al.
Published: (2020-08-01)

Case Report: Re-Treatment With Lu-DOTATATE in Neuroendocrine Tumors
by: Elena María Vida Navas, et al.
Published: (2021-04-01)

The eye of the beholder: orbital metastases from midgut neuroendocrine tumors, a two institution experience
by: Satya Das, et al.
Published: (2018-12-01)

68Ga-DOTATATE positron emission tomography/computed tomography to detect the recurrence of phosphaturic mesenhcymal tumor-induced osteomalacia
by: Manav I Bhalla, et al.
Published: (2020-01-01)

Current treatment options for gastroenteropancreatic neuroendocrine tumors with a focus on the role of lanreotide
by: Beata Kos-Kudła, et al.
Published: (2017-06-01)

Can a penalized-likelihood estimation algorithm be used to reduce the injected dose or the acquisition time in 68Ga-DOTATATE PET/CT studies?
by: Alexandre Chicheportiche, et al.
Published: (2021-02-01)

Gallium‐68 DOTATATE Production with Automated PET Radiopharmaceutical Synthesis System: A Three Year Experience
by: Alireza Aslani, et al.
Published: (2014-10-01)

Metastatic clear cell renal cell carcinoma demonstrating intense uptake on 68Ga-DOTATATE positron emission tomography: Three case reports and a review of the literature
by: David P Nadebaum, et al.
Published: (2018-01-01)

Multi-curie production of gallium-68 on a biomedical cyclotron and automated radiolabelling of PSMA-11 and DOTATATE
by: Helge Thisgaard, et al.
Published: (2021-01-01)

Radiological Imaging of Gastro-Entero-Pancreatic Neuroendocrine Tumors. The Review of Current Literature Emphasizing the Diagnostic Value of Chosen Imaging Methods
by: Gabriela Półtorak-Szymczak, et al.
Published: (2021-06-01)

Evaluation of Kidney Dose in Neuroendocrine Tumors Patients after Peptide Receptor Radionuclide Therapy using 177Lu-DOTATATE
by: N.R. Hidayati, et al.
Published: (2019-12-01)

Paget’s Disease Mimicking Bone Metastasis in a Patient with Neuroendocrine Tumor on 68Ga-DOTANOC PET/CT
by: Naciye Sinem Gezer, et al.
Published: (2016-07-01)

177Lu-DOTATATE peptide receptor radionuclide therapy in metastatic or advanced and inoperable primary neuroendocrine tumors of rare sites
by: Pradeep Thapa, et al.
Published: (2017-01-01)

Symptoms and Quality of Life in Gastroenteropancreatic Neuroendocrine Tumours
by: Rajaventhan Srirajaskanthan, et al.
Published: (2014-03-01)

The Use of 68Ga-DOTATATE PET/CT in the Non-invasive Diagnosis of Optic Nerve Sheath Meningioma: A Case Report
by: Karine A. Al Feghali, et al.
Published: (2018-10-01)

Clinicopathological features and prognosis of gastroenteropancreatic neuroendocrine neoplasms in a Chinese population: a large, retrospective single-centre study
by: Meng Zhang, et al.
Published: (2017-07-01)

A novel read methodology to evaluate the optimal dose of 68Ga-satoreotide trizoxetan as a PET imaging agent in patients with gastroenteropancreatic neuroendocrine tumours: a phase II clinical trial
by: Colin G. Miller, et al.
Published: (2021-09-01)

Automated liver lesion detection in 68Ga DOTATATE PET/CT using a deep fully convolutional neural network
by: Jonathan Wehrend, et al.
Published: (2021-10-01)

Clinicopathological heterogeneity between primary and metastatic sites of gastroenteropancreatic neuroendocrine neoplasm
by: Huiying Shi, et al.
Published: (2020-09-01)

Cannot write session to /tmp/vufind_sessions/sess_45o463qavqa1n7pug96pund5td